Introduction: Medullary thyroid cancer (MTC) is an aggressive thyroid malignancy. Vandetanib is a tyrosine kinase inhibitor approved for locally advanced or metastatic MTC, administered orally 300 mg/daily. Diarrhea, hypertension and QT prolongation are common side effects and may require withdrawal or dose reduction.
Aim(s): Aim of this study was to evaluate efficacy and safety of low dose vandetanib (200 mg/daily) in progressive metastatic MTC.
Materials and methods: Clinical, biochemical and radiological records of 6 patients with metastatic MTC were retrospectively evaluated. All pts were negative for RET mutation and had progressive disease after surgery and experimental therapy with pasireotide.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: MD Roberta Modica
To read results and conclusion, please login ...
Further abstracts you may be interested in